AlphAIAlphAI — Financial news for AI agents
fool.com$SRTS

Sensus (SRTS) Q2 2026 Earnings Call Transcript

Sensus Healthcare (SRTS) reported Q2 2026 revenue of $2.3M, down 68.5% YoY, due to fewer units sold and delayed financing approvals. Units sold decreased to 11 from 19 in Q2 2025. Gross margin was 34.8%, and net loss was $8.7M. The company expects 20+ units per quarter in Q3 and Q4. Cash reserves decreased to $15.2M. Management criticized a bank for financing delays and plans to focus on recurring revenue models and international expansion.

Original reporting
fool.com
Published Aug 20, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 12:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Sensus (SRTS) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$SRTSBearishMed
01

Why it matters

The earnings miss and guidance suggest short-term weakness, but management's focus on unit guidance and new market expansion may offer longer-term upside.

02

Market read

Micro‑cap medical device stock with immediate earnings-driven volatility; relevance primarily to sector‑focused traders.

03

What to watch

Potential reimbursement code changes and recurring revenue model could improve margins over time.

Relevance 6/10Novelty 7/10Timing: post-earnings Q2 2026 release

Background

Sensus Healthcare reported its Q2 2026 results, noting a sharp revenue decline due to financing delays and a shift toward recurring revenue models.

Company-level read

Ticker impact

$SRTSBearishMedium confidence
Context

Q2 2026 earnings release showing a 68.5% revenue drop, $8.7M net loss and guidance on unit shipments.

Expected impact

Potential near-term downside pressure with a possible rebound if Q3 unit shipments meet guidance.

Evidence & confidence

Earnings miss and weak guidance dominate, but management expects financing approvals to improve Q3 results.

Market effects

Sector

Highlights challenges in the superficial radiation therapy market and may affect peer valuations.

Regional

Emphasis on Asia‑Pacific expansion could influence regional healthcare equipment investors.

Global

Limited to niche medical device sector; broader market impact minimal.

Counterpoint

What could challenge this read

If financing issues resolve quickly, the stock could outperform peers on upside potential.

Key entities

  • Executive
    Joe Sardano

    Chairman and CEO, commented on financing delays.

  • Executive
    Michael Sardano

    President and CCO, discussed recurring revenue strategy.

Read at source← All news

Related articles

$SRTSMed

Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre

SEC EDGAR 8-K
$SRTSMed

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase

SEC EDGAR 8-K
$AGROHighAI 8/10

Adecoagro (AGRO) Q3 2026 Earnings Call Transcript

Adecoagro reported Q3 2026 earnings, with gross sales of $591M and year-to-date sales of $1.5B. Fertilizers drove growth, offsetting lower Sugar, Ethanol, and Energy revenues. Adjusted EBITDA reached a 9-month high. The company acquired the Caarapó mill, expecting it to boost crushing volumes. Fertilizers and Food/Agriculture segments performed strongly, while Sugar/Ethanol faced cost pressures and lower sales.

finance.yahoo.com
$FIGRHighAI 8/10

Figure Tech (FIGR) Q3 2026 Earnings Call Transcript

Figure Tech (FIGR) reported Q3 2026 earnings with $5.8B volume, up 107% YoY, and 58% EBITDA margin. The company processed $5.1B organically and $0.7B from Kiavi. Figure Connect accounted for 72% of volume. They added 612 partners, expanded SMB business to $500M run rate, and launched new AI-driven products. Kiavi acquisition added $8B volume and new asset classes, expected to be accretive. The company saw resilience in higher interest rates, with strong investor demand and securitizations.

finance.yahoo.com
$CDNLMedAI 8/10

Cardinal Infra (CDNL) Q3 2026 Earnings Call Transcript

Cardinal Infra (CDNL) reported Q3 2026 revenue of $202M, up 65%, but adjusted EBITDA fell to $9M from $21M YoY. The company withdrew full-year guidance due to project estimate revisions and operational challenges. The board authorized a $50M share repurchase program. CFO Mike Rowe will step down, and the company is focusing on improving execution and profitability.

finance.yahoo.com